In Vitro Selection of RNA Aptamers Derived from a Genomic Human Library against the TAR RNA Element of HIV-1

Watrin, Marguerite; Pelchrzim, Frederike von; Dausse, Eric; Schroeder, Renée; Toulmé, Jean‐Jacques

doi:10.1021/bi802373d

Cited by 30 publications

(23 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analysis of 64 variants of LNA/2′-O-Me modified aptamers had shown that the combination of these modifications results in higher binding affinity as compared with the unmodified RNA aptamer (Di Primo et al, 2007). To obtain genomic RNA aptamers that might reflect natural interactions of the TAR fragment with human RNA transcripts, a genomic SELEX was conducted, taking in vitro transcripts of full human genome as a starting library (Watrin et al, 2009). The hairpin-forming aptamers obtained during this process possessed high affinity to their targets ( K d from 4 to 297 nM).…”

Section: Antiviral Aptamersmentioning

confidence: 99%

Aptamers against pathogenic microorganisms

Davydova

Vorobjeva

Pyshnyi

et al. 2015

Critical Reviews in Microbiology

View full text Add to dashboard Cite

An important current issue of modern molecular medicine and biotechnology is the search for new approaches to early diagnostic assays and adequate therapy of infectious diseases. One of the promising solutions to this problem might be a development of nucleic acid aptamers capable of interacting specifically with bacteria, protozoa, and viruses. Such aptamers can be used for the specific recognition of infectious agents as well as for blocking of their functions. The present review summarizes various modern SELEX techniques used in this field, and of several currently identified aptamers against viral particles and unicellular organisms, and their applications. The prospects of applying nucleic acid aptamers for the development of novel detection systems and antibacterial and antiviral drugs are discussed.

show abstract

Section: Antiviral Aptamersmentioning

confidence: 99%

Aptamers against pathogenic microorganisms

Davydova

Vorobjeva

Pyshnyi

et al. 2015

Critical Reviews in Microbiology

View full text Add to dashboard Cite

show abstract

“…The lower nanomolar dissociation constant (K D = 30 nM at 3 mM magnesium) of the selected RNA aptamers was attributed to closing of the aptamer loop by the consensus G and A residues [87]. Moreover, anti-TAR RNA aptamers were isolated from a genomic human library [88]. Theoretically, a genomic SELEX library contains all cellular RNA transcripts that can identify putative functional interactions involving RNA motifs [154].…”

Section: Aptamers As Antiviral Therapeuticsmentioning

confidence: 99%

“…In the case of TAR aptamers, one of the selected aptamers, (a1), formed a complex with TAR through a kissing interaction and had ~4-fold lower dissociation constant than that of a previously identified aptamer, R06 (K D : 4 nM vs . 17 nM) [88]. …”

Section: Aptamers As Antiviral Therapeuticsmentioning

confidence: 99%

Aptamer-Based Therapeutics: New Approaches to Combat Human Viral Diseases

2013

View full text Add to dashboard Cite

Viruses replicate inside the cells of an organism and continuously evolve to contend with an ever-changing environment. Many life-threatening diseases, such as AIDS, SARS, hepatitis and some cancers, are caused by viruses. Because viruses have small genome sizes and high mutability, there is currently a lack of and an urgent need for effective treatment for many viral pathogens. One approach that has recently received much attention is aptamer-based therapeutics. Aptamer technology has high target specificity and versatility, i.e., any viral proteins could potentially be targeted. Consequently, new aptamer-based therapeutics have the potential to lead a revolution in the development of anti-infective drugs. Additionally, aptamers can potentially bind any targets and any pathogen that is theoretically amenable to rapid targeting, making aptamers invaluable tools for treating a wide range of diseases. This review will provide a broad, comprehensive overview of viral therapies that use aptamers. The aptamer selection process will be described, followed by an explanation of the potential for treating virus infection by aptamers. Recent progress and prospective use of aptamers against a large variety of human viruses, such as HIV-1, HCV, HBV, SCoV, Rabies virus, HPV, HSV and influenza virus, with particular focus on clinical development of aptamers will also be described. Finally, we will discuss the challenges of advancing antiviral aptamer therapeutics and prospects for future success.

show abstract

“…(104) Such a kissing aptamer targeted to the trans-activating responsive (TAR) element of HIV-1 displayed both high affinity and exquisite specificity (5). RNA aptamers produced in situ in HeLaP4 cells from an expression vector inhibit TAR-dependent expression of a reporter gene.…”

Section: Rna Nanoparticles In Therapeuticsmentioning

confidence: 99%

A Boost for the Emerging Field of RNA Nanotechnology

et al. 2011

Self Cite

View full text Add to dashboard Cite

This Nano Focus article highlights recent advances in RNA nanotechnology as presented at the First International Conference of RNA Nanotechnology and Therapeutics, which took place in Cleveland, OH, USA (October 23–25, 2010) (), chaired by Peixuan Guo and co-chaired by David Rueda and Scott Tenenbaum. The conference was the first of its kind to bring together more than 30 invited speakers in the frontier of RNA nanotechnology from France, Sweden, South Korea, China, and throughout the United States to discuss RNA nanotechnology and its applications. It provided a platform for researchers from academia, government, and the pharmaceutical industry to share existing knowledge, vision, technology, and challenges in the field and promoted collaborations among researchers interested in advancing this emerging scientific discipline. The meeting covered a range of topics, including biophysical and single-molecule approaches for characterization of RNA nanostructures; structure studies on RNA nanoparticles by chemical or biochemical approaches, computation, prediction, and modeling of RNA nanoparticle structures; methods for the assembly of RNA nanoparticles; chemistry for RNA synthesis, conjugation, and labeling; and application of RNA nanoparticles in therapeutics. A special invited talk on the well-established principles of DNA nanotechnology was arranged to provide models for RNA nanotechnology. An Administrator from National Institutes of Health (NIH) National Cancer Institute (NCI) Alliance for Nanotechnology in Cancer discussed the current nanocancer research directions and future funding opportunities at NCI. As indicated by the feedback received from the invited speakers and the meeting participants, this meeting was extremely successful, exciting, and informative, covering many groundbreaking findings, pioneering ideas, and novel discoveries.

show abstract

In Vitro Selection of RNA Aptamers Derived from a Genomic Human Library against the TAR RNA Element of HIV-1

Cited by 30 publications

References 45 publications

Aptamers against pathogenic microorganisms

Aptamers against pathogenic microorganisms

Aptamer-Based Therapeutics: New Approaches to Combat Human Viral Diseases

A Boost for the Emerging Field of RNA Nanotechnology

Contact Info

Product

Resources

About